phase 2_completion
saveGuangzhou Panyu Central Hospital — aumolertinib mesylate (Phase II Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Lung Adenocarcinoma, Non-Small Cell Lung Cancer
Data sources
globaldata
Found something off?
comments(0)
5-min edit window · permanent after that